Patent 11566277
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
Active provider: Google · gemini-2.5-pro
No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.
Cases on file (1)
Group view →Specific litigation cases in our database that name US patent 11566277. The free-form analysis below may also discuss cases beyond this list.
- 10x Genomics, Inc. et al. v. Element Biosciences, Inc.filed May 8, 2026U.S. District Court for the District of Delawarepending
Defendants: Element Biosciences, Inc.
Litigation summary
Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.
IV. Known Litigation
As of May 12, 2026, U.S. Patent 11,566,277 is involved in one known litigation case. The details are as follows:
Case 1: 10X Genomics, Inc. et al v. Element Biosciences, Inc.
- Plaintiff(s): 10X Genomics, Inc. and President and Fellows of Harvard College
- Defendant(s): Element Biosciences, Inc.
- Jurisdiction: U.S. District Court for the District of Delaware
- Case Number: 1:26-cv-00538
- Filing Date: May 8, 2026
- Status: Active/Pending. The complaint was filed on May 8, 2026. According to the docket, the summons was served on Element Biosciences, Inc. the same day, with an answer due by May 29, 2026.
- Details: The lawsuit alleges that Element Biosciences' AVITI24 multiomic analysis platform and Teton chemistry infringe on four patents, including U.S. Patent 11,566,277. The plaintiffs are seeking a permanent injunction or an ongoing royalty for future infringement, and lost profits or a reasonable royalty for past infringement. In a public statement, Element Biosciences has responded that it "strongly disagrees with the allegations" and "will vigorously defend its technology."
Generated 5/12/2026, 6:46:52 AM